{"id":"mk0557","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ghrelin is an endogenous hormone that stimulates hunger and appetite through the growth hormone secretagogue receptor 1a (GHS-R1a). By antagonizing this receptor, MK0557 suppresses the hunger signal, leading to reduced caloric intake and potential weight loss. This mechanism targets a distinct pathway from monoamine-based or GLP-1-based weight loss agents.","oneSentence":"MK0557 is a ghrelin receptor (GHS-R1a) antagonist that blocks the orexigenic signaling of ghrelin to reduce appetite and food intake.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:07.008Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Obesity or overweight with weight-related comorbidities"}]},"trialDetails":[{"nctId":"NCT00092859","phase":"PHASE3","title":"A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-08","conditions":"Obesity","enrollment":1500},{"nctId":"NCT00533481","phase":"PHASE2","title":"Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-02","conditions":"Obesity","enrollment":497},{"nctId":"NCT00533598","phase":"PHASE2","title":"A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-09","conditions":"Obesity","enrollment":""},{"nctId":"NCT00482430","phase":"PHASE2","title":"MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09","conditions":"Paranoid Schizophrenia, Schizophrenia","enrollment":50},{"nctId":"NCT00092872","phase":"PHASE3","title":"A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-11","conditions":"Obesity","enrollment":359}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK0557","genericName":"MK0557","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK0557 is a ghrelin receptor (GHS-R1a) antagonist that blocks the orexigenic signaling of ghrelin to reduce appetite and food intake. Used for Obesity or overweight with weight-related comorbidities.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}